IHC TESTING FOR SEBACEOUS NEOPLASMS: A RAPID REVIEW OF SCREENING ACCURACY AND APPLICATION OF GRADE

I Natoli, M Alvarado. Kaiser Permanente (Southern California), Pasadena, CA, United States

10.1136/bmjqs-2013-002293.163

Background Lynch syndrome is the most common form of inherited colorectal cancer (~3% of cases). Among patients with colorectal cancer tumours, immunohistochemistry (IHC) for mismatch repair proteins has demonstrated validity and utility as a screening test for Lynch syndrome, although guidelines differ on whether screening should be limited to patients at increased risk. IHC can be performed on other Lynch-related tumours, including sebaceous neoplasms, although it is unclear if IHC should be part of routine pathologic evaluation for sebaceous neoplasms.

Objectives To determine the clinical validity and utility of routine IHC testing of sebaceous neoplasms to inform development of guidance on screening for the Muir-Torre variant of Lynch syndrome.

Methods An AHRQ-based analytic framework was created. We conducted comprehensive searches to identify clinical studies that evaluated IHC testing of sebaceous neoplasms as a method of screening for Muir-Torre syndrome. GRADE was used for critical appraisal.

Results The body of evidence included 14 clinically heterogeneous studies representing approximately 300 patients. The weighted mean screen positive rate was 37%. Few studies reported measures of clinical validity, although half of the studies reported the prevalence of visceral malignancy and/or results of germline mutation testing, suggesting possible reporting bias.

Discussion The overall body of evidence is of low quality and does not provide conclusive evidence for or against IHC testing for sebaceous neoplasms, either as a routine protocol or only among patients at high risk for Muir-Torre syndrome.

Implications for Guideline Developers/Users Rapid evidence reviews are useful for informing guidance development on rare/genetic conditions.

DEVELOPING A CUSTOMISED WEB-BASED DATA EXTRACTION TOOL USING AN EXISTING CUSTOMER RELATIONSHIP SERVICE: THINKING OUTSIDE THE BOX

E Nagler, V Lébaut, M Haller, S van der Veer, D Bolignano, W Van Biesen. Renal Division, Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium; ERBP, Ghent University Hospital, Ghent, Belgium; 34 Consulting, Mechelen, Belgium; 4Section for Clinical Biometrics, Medical University of Vienna, Vienna, Austria; 5Department of Medical Informatics, Academic Medical Center, Amsterdam, The Netherlands; 6CNR-BIBIT Reggio Calabria, Italy; 7Nephrology Department, University of Medicine and Pharmacy, Lasi, Romania

10.1136/bmjqs-2013-002293.164

Background Standardised duplicate data extraction and tabulation can be challenging for organisations that develop multiple guidelines involving multiple and remote systematic review teams simultaneously.

Objectives To develop a web-based tool for facilitating duplicate data extraction and efficient discrepancy resolution.

Methods Based on previous experiences with word-processing and spreadsheet tools, European Renal Best Practice listed their system requirements and collaborated with a consultancy company to identify appropriate customisable software.

Results We wanted the system to: be web-based, guide reviewers through a standardised data extraction form, be easy-to-use and manage, allow enough flexibility to accommodate different guideline topics, be free-of-charge and easily accessible from different locations without the need for downloading software. We identified a customer relationship management service, Salesforce, that allowed us to build a data extraction module using their backbone structure. It incorporates centralised management of multiple systematic reviews simultaneously, batch allocation of studies to individual reviewers, guided customised point-and-click data extraction, generation of tables to assist discrepancy resolution with easy export to a csv-file extension format.

Discussion This project represents a continuous effort to facilitate efficient and high-quality systematic reviewing with participation of our guideline development groups throughout the systematic reviewing process. A first version of the system is currently being evaluated.

Implications for Guideline Developers/Users Customising existing software for guideline development purposes might be an attractive and inexpensive alternative to developing new tools for data extraction when full participation of the guideline development group in the systematic review process is desired.
Abstracts

P111 A WORKFLOW CHECKLIST FOR IMPROVING MANAGEMENT OF THE GUIDELINE DEVELOPMENT PROCESS

M Haller, E Nagler, J van der Veer, Nistor, D Bolignano, W Van Biesen. European Renal Best Practice, Ghent University Hospital, Ghent, Belgium; Center for Medical Statistics (CEMSIS), Medical University Vienna, Vienna, Austria; Renal Division, Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium; Academic Medical Center, Department of Medical Informatics, Amsterdam, The Netherlands; Nephrology Department, GT, Papa University of Medicine and Pharmacy, Lasi, Romania; CNR-IBIM, Clinical Epidemiology and Physiopathology of Renal Diseases Reggio, Calabria, Italy.

Background Keeping track of progress and meeting deadlines can be difficult for organisations that simultaneously develop multiple guidelines involving multiple systematic review teams. Objectives To improve planning, organising and managing of guideline development projects by creating a standardised workflow checklist. Methods In a one-day meeting, the five guideline development methodologists, the chairman and the editorial assistant identified the main steps involved in the guideline development process. For each step, they identified specific tasks and ordered them chronologically. All decisions were made based on group consensus. The identified steps and tasks formed the basic elements of the workflow checklist. Results We identified the need for two separate checklists per guideline development project; one for overall workflow and one for each clinical question covered by the guideline. The overall guideline development workflow checklist comprised 42 tasks organised in 11 sequential steps, including items such as topic selection, composition of the guideline development group, and framing the questions. For each clinical question we identified 27 tasks organised in 8 sequential steps, excluding steps already covered by the overall workflow. Discussion This workflow checklist represents a first step in developing a standardised project management strategy to improve efficient management of the guideline development process. Further development of this tool involves selecting appropriate software for practical implementation applicable not only for our own means but also for those of other groups. Implications for Guideline Developers/User The workflow checklist will improve efficient management of guideline development and allows transparent and up-to-date communication of its progress.

P114 THE QUALITY OF EVIDENCE OF SYSTEMATIC REVIEWS OF TRADITIONAL CHINESE MEDICINE: A CROSS-SECTIONAL STUDY

Y Chen, Q Wu, X Wang, Q Wang, D Wei, L Yao, F Liang, M Wang, K Yang. Evidence-Based Medicine Center of Lanzhou University, Lanzhou, China; First Hospital of Lanzhou University, Lanzhou, China.

Background There has been an increasing interest in systematic reviews of traditional Chinese medicine (SR-TCM) over the past 10 years. Little is known about the quality of evidence of SR-TCM. Methods GRADE (Grading of Recommendations Assessment, Development and Evaluation) system is a tool to rate evidence quality of SRs and other evidence body. We searched CBM (China Biomedicine Database) from 1978 to 2012 and included all SR-TCM in the field of cancer treatment. We used GRADE system to assess the quality of evidence of those SRs. Two reviewers independently screened the titles and abstracts of identified studies. Full texts of potentially included articles were further assessed. Disagreements were resolved by discussion. Results The preliminary results showed that the quality of evidence of SR-TCM were: high (1%), moderate (25%), low (50%), very low (24%). We also compared with the quality of evidence of SRs published in Chinese medical journals (5%, 27%, 49%, 19%) and Cochrane SRs (5%, 27%, 49%, 19%). Risk of bias, inconsistency and publication bias were the major factors for downgrading evidence of SR-TCM. Conclusion More and more SR-TCM had been published in Chinese medical journals, however, the proportion of high quality evidence is lower and the very low quality evidence is higher compared with national and international levels.

P115 HOW MANY CLUSTER RANDOMIZED CONTROLLED TRIALS WERE USED IN CLINICAL PRACTICE GUIDELINES?

Y Chen, Q Wu, X Wang, Q Wang, D Wei, L Yao, F Liang, M Wang, Y Yang. Evidence-Based Medicine Center of Lanzhou University, Lanzhou, China; First Hospital of Lanzhou University, Lanzhou, China; Chinese GRADE Center, Lanzhou, China.

Background There has been an increasing interest in cluster randomised controlled trial (CRT) over the past 20 years. Little is known about how many CRTs were used by clinical practice guidelines. Methods We searched National Guideline Clearinghouse (NGC) which is a public resource for evidence-based clinical practice guidelines on December 31, 2012. We selected guidelines which provide MEDLINE full-text linking and then we checked all references cited by those guidelines. Results We included 564 guidelines and they contained 57495 references. We identified 13 guidelines cited 17 cluster randomised controlled trials as their references. Guidelines are about primary care, cancer, obesity, breastfeeding, cardiovascular and orthopaedic diseases. Screening studies accounts for as much as 35% (6) of all CRTs. Conclusion Cluster randomised controlled trial is considered as the golden standard to assess the effect of intervention in health research. Based on the retrieval strategy study for cluster randomised controlled trial we developed, we estimated that there are about 8000 CRTs in Medline, however, only 17 CRTs were used or cited by clinical practice guidelines, the reasons of low utilisation of CRTs in guidelines are not being investigated and we are going to present the final findings.

P117 UNIFORMITY IN ANAESTHESIOLOGY RECOMMENDATIONS


Background There has been a decreasing interest in systematic reviews of traditional Chinese medicine (SR-TCM) over the past 10 years. Little is known about the quality of evidence of SR-TCM. Methods GRADE (Grading of Recommendations Assessment, Development and Evaluation) system is a tool to rate evidence quality of SRs and other evidence body. We searched CBM (China Biomedicine Database) from 1978 to 2012 and included all SR-TCM in the field of cancer treatment. We used GRADE system to assess the quality of evidence of those SRs. Two reviewers independently screened the titles and abstracts of identified studies. Full texts of potentially included articles were further assessed. Disagreements were resolved by discussion. Results The preliminary results showed that the quality of evidence of SR-TCM were: high (1%), moderate (25%), low (50%), very low (24%). We also compared with the quality of evidence of SRs published in Chinese medical journals (5%, 27%, 49%, 19%) and Cochrane SRs (5%, 27%, 49%, 19%). Risk of bias, inconsistency and publication bias were the major factors for downgrading evidence of SR-TCM. Conclusion More and more SR-TCM had been published in Chinese medical journals, however, the proportion of high quality evidence is lower and the very low quality evidence is higher compared with national and international levels.